Silver Creek Pharmaceuticals Receives FDA Fast Track Designation for Scp776 in Acute Ischemic StrokeSOUTH SAN FRANCISCO, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Silver Creek Pharmaceuticals, Inc. (Silver Creek), a clinical-stage biotechnology company developing growth factor-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to scp776, its investigational therapy for acute ischemic stroke, a condition with limited treatment options beyond reperfusion.
